<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066872</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000320513</org_study_id>
    <secondary_id>CRUK-LON-SINS-C7484/A2869</secondary_id>
    <secondary_id>EU-20205</secondary_id>
    <nct_id>NCT00066872</nct_id>
  </id_info>
  <brief_title>Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer</brief_title>
  <official_title>A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune&#xD;
      system and stop cancer cells from growing. It is not yet known if topical imiquimod is more&#xD;
      effective than surgery in treating basal cell skin cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well topical imiquimod works&#xD;
      compared to surgery in treating patients with basal cell skin cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the rate of local recurrence at 3 years in patients with nodular or superficial&#xD;
           basal cell skin cancer treated with imiquimod 5% cream vs excisional surgery.&#xD;
&#xD;
        -  Compare recurrence at 6 months and 1, 2, and 5 years in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the time to first recurrence in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the aesthetic appearance of lesion sites in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare pain in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center and lesion type (nodular vs superficial). Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive topical imiquimod to a single lesion once daily for 6 weeks for&#xD;
           a superficial lesion or 12 weeks for a nodular lesion. Patients with early treatment&#xD;
           failure or recurrence are offered surgical excision.&#xD;
&#xD;
        -  Arm II: Patients undergo surgical excision. Patients are followed at 6, 12, and 18&#xD;
           weeks, every 6 months for 1 year, annually for 2 years, and then at 5 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of local recurrence at 3 years after start of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of basal cell cancer (BCC) at 1, 2, and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence up to 5 years from completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aesthetic appearance of lesion site as measured by participant and blind observer using 5-point Likert scale at 6 months, and then years 1-3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at lesion site as measured by 6-point scale daily during treatment, and then 16 weeks after the completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness assessed up to 3 or 5 years</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary basal cell skin carcinoma&#xD;
&#xD;
               -  Nodular or superficial lesion(s)*&#xD;
&#xD;
               -  Located in low-risk areas NOTE: *Any number of lesions are allowed but only 1&#xD;
                  lesion per patient is selected for the study&#xD;
&#xD;
          -  No genetic or nevoid conditions (e.g., Gorlin's syndrome)&#xD;
&#xD;
          -  No morphoeic (microinfiltrative) histology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 1 month after&#xD;
             study participation&#xD;
&#xD;
          -  No allergy to any of the study interventions&#xD;
&#xD;
          -  No life-threatening disease&#xD;
&#xD;
          -  Must be available for study follow-up for up to 3 years&#xD;
&#xD;
          -  Must have access to a telephone&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in any other experimental trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Ozolins, MS</last_name>
    <affiliation>Queen's Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chesterfield Royal Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>England</state>
        <zip>S44 5BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solihull Hospital</name>
      <address>
        <city>Solihull</city>
        <state>England</state>
        <zip>B91 2JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials. 2010 Apr 21;11:42. doi: 10.1186/1745-6215-11-42.</citation>
    <PMID>20409337</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>basal cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

